CRISPR Therapeutics AG

NASDAQ:CRSP   9:43:49 AM EDT
188.81
+0.32 (+0.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)13.96B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.36 Million
Adjusted EPS-$1.27
See more estimates
10-Day MA$189.01
50-Day MA$151.78
200-Day MA$97.42
See more pivots

CRISPR Therapeutics AG Stock, NASDAQ:CRSP

BAARERSTRASSE 14, ZUG, SWITZERLAND CH-6300
Switzerland
Phone: 6173154600
Number of Employees: 188
www.crisprtx.com

Description

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.